Payment overview · 2025
General Payments
$778.07
50 reported records · 12 companies
Healthcare provider profile · identity verified
John E Nix, MD
Allopathic & Osteopathic Physicians|Family Medicine · TEXARKANA, TX · NPI 1972598837
Verified facts
What the public records show
CMS Open Payments records show John E Nix, MD received $778.07 in general payments during 2025 across 50 reported records.
ABBVIE INC. accounted for 26.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 208 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 156 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $202.97 | 26.1% | 19 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $131.36 | 16.9% | 8 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $90.44 | 11.6% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $86.43 | 11.1% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $78.59 | 10.1% | 5 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $40.77 | 5.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $39.09 | 5.0% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $28.76 | 3.7% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $26.10 | 3.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.90 | 2.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.65 | 2.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.01 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $778.07 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $131.36 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $123.30 | 12 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $120.56 | 11 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $97.36 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $90.44 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $86.43 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $56.11 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $48.26 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $40.77 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $39.09 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $34.00 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.33 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.33 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $28.76 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $26.10 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $23.56 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $23.56 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.65 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 156 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 208 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
208 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
156 | 40 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
17 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 674 | 127 |
| Atorvastatin Calcium | Atorvastatin Calcium | 597 | 174 |
| Amlodipine Besylate | Amlodipine Besylate | 517 | 132 |
| Lisinopril | Lisinopril | 444 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 414 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 392 | 107 |
| Potassium Chloride | Potassium Chloride | 368 | 100 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 362 | 86 |
| Furosemide | Furosemide | 300 | 92 |
| Gabapentin | Gabapentin | 284 | 73 |
| Omeprazole | Omeprazole | 282 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 279 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 268 | 64 |
| Meloxicam | Meloxicam | 249 | 86 |
| Metformin Hcl Er | Metformin Hcl | 218 | 56 |
| Ozempic | Semaglutide | 208 | 40 |
| Losartan Potassium | Losartan Potassium | 194 | 61 |
| Escitalopram Oxalate | Escitalopram Oxalate | 191 | 56 |
| Pravastatin Sodium | Pravastatin Sodium | 190 | 51 |
| Glimepiride | Glimepiride | 189 | 50 |
| Tizanidine Hcl | Tizanidine Hcl | 177 | 67 |
| Metoprolol Tartrate | Metoprolol Tartrate | 159 | 38 |
| Eliquis | Apixaban | 156 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 155 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 149 | 31 |
| Simvastatin | Simvastatin | 148 | 42 |
| Tramadol Hcl | Tramadol Hcl | 145 | 40 |
| Duloxetine Hcl | Duloxetine Hcl | 141 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 133 | 30 |
| Azithromycin | Azithromycin | 132 | 112 |
| Alprazolam | Alprazolam | 131 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 131 | 36 |
| Carvedilol | Carvedilol | 129 | 36 |
| Metformin Hcl | Metformin Hcl | 126 | 41 |
| Warfarin Sodium | Warfarin Sodium | 120 | 14 |
| Sertraline Hcl | Sertraline Hcl | 114 | 28 |
| Methylprednisolone | Methylprednisolone | 109 | 99 |
| Allopurinol | Allopurinol | 107 | 27 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 100 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 99 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 87 | 32 |
| Celecoxib | Celecoxib | 86 | 27 |
| Ropinirole Hcl | Ropinirole Hcl | 86 | 18 |
| Mounjaro | Tirzepatide | 84 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 77 | 70 |
| Farxiga | Dapagliflozin Propanediol | 74 | 14 |
| Fenofibrate | Fenofibrate | 74 | 17 |
| Montelukast Sodium | Montelukast Sodium | 72 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | 17 |
| Amoxicillin | Amoxicillin | 67 | 59 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 67 | 14 |
| Ibuprofen | Ibuprofen | 66 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 65 | 17 |
| Glipizide | Glipizide | 63 | 15 |
| Synthroid | Levothyroxine Sodium | 61 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 58 | 19 |
| Lorazepam | Lorazepam | 56 | 12 |
| Ramipril | Ramipril | 53 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 52 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 52 | 23 |
| Bupropion Xl | Bupropion Hcl | 51 | suppressed |
| Temazepam | Temazepam | 49 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 48 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 46 | 41 |
| Atenolol | Atenolol | 45 | suppressed |
| Jardiance | Empagliflozin | 45 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 40 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 38 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | 12 |
| Glipizide Er | Glipizide | 37 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 13 |
| Valacyclovir | Valacyclovir Hcl | 37 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 36 | suppressed |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Valsartan | Valsartan | 36 | 11 |
| Prednisone | Prednisone | 34 | 29 |
| Clonazepam | Clonazepam | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Ezetimibe | Ezetimibe | 32 | 11 |
| Spironolactone | Spironolactone | 32 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 32 | 13 |
| Finasteride | Finasteride | 31 | 11 |
| Propranolol Hcl | Propranolol Hcl | 31 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Baclofen | Baclofen | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 22 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 18 |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Cefdinir | Cefdinir | 24 | 22 |
| Ondansetron Odt | Ondansetron | 24 | 20 |
| Colchicine | Colchicine | 23 | suppressed |
| Diazepam | Diazepam | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 11 |
| Pregabalin | Pregabalin | 23 | suppressed |
| Sotalol | Sotalol Hcl | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 19 |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Fluconazole | Fluconazole | 18 | 13 |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 17 | 17 |
| Lactulose | Lactulose | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 12 |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | 11 |
| Novolin R Flexpen | Insulin Regular, Human | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | 12 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $778.07 · 50 records | ABBVIE INC. | CAPVAXIVE, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FREESTYLE LIBRE 3, GARDASIL 9, INSPIRE, Korlym, LINZESS, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, Senza, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error